bumetanide / Generic mfg. - LARVOL DELTA

Chloride-dependent mechanisms contribute to urinary bladder smooth muscle contractility: Pharmacological and molecular evidence from rat bladder tissue. (PubMed, Tzu Chi Med J) - "Norepinephrine (NE)-induced contractions were evaluated with pretreatment of chloride transport inhibitors (bumetanide, HEPES without bicarbonate, and ethacrynic acid) and chloride channel blockers (4,4'-diisothiocyano-2,2'-stilbene-disulfonic acid, anthracene-9-carboxylic acid, and niflumic acid) at different concentrations. Expression of ClC-3 and CLCA4 in urothelial and SM layers further suggests that chloride-dependent regulation may involve multiple bladder compartments. Although the precise molecular mechanisms remain incompletely defined, these findings support further investigation into chloride-dependent signaling pathways in bladder physiology and dysfunction."

Journal • Preclinical

Bumetanide/Synthetic Saponite Composites: Performant Systems for Enhanced Drug Dissolution Rate. (PubMed, Molecules) - "The complete release of the bumetanide dose, not achieved in sufficiently short times for all the fluids considered, is reached in the formulation with appropriate excipients. Bumetanide/saponite composites revealed performant and tuneable systems for bumetanide solubility and dissolution rate enhancement."

Journal

With-No-Lysine Kinases Coordinate Cl– secretion across human airway epithelia (NACFC 2026) - "The bumetanide-sensitive relationship between basolateral [Cl–] and short-circuit current was sigmoidal, indicating that Cl– flow followed the kinetics of NKCC1 (with low- and high-affinity binding sites) rather than CFTR (with Michaelis-Menten kinetics)... Thus, WNK coordinates the crosstalk between the apical and basolateral membranes, thereby adjusting NKCC1 activity to support CFTR activity."

Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases • CFTR

Acute Peripartum Cardiomyopathy With Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation: A Case Report Of Complete Ventricular Recovery (HFSA 2026) - "With disease progression, VA-ECMO provides temporary biventricular support as a bridge to recovery, leveraging the myocardial regeneration potential unique to PPCM.Case Presentation: A 35-year-old G1P0 woman with a history of Hodgkin lymphoma treated with doxorubicin-based chemotherapy and IVF-conceived dichorionic diamniotic twin pregnancy presented for delivery...Bromocriptine was initiated for lactation suppression and cardioprotection...VA-ECMO provided essential biventricular support; concurrent bumetanide and clevidipine addressed LV afterload elevation from retrograde ECMO flow... This case reinforces the importance of early mechanical circulatory support as a bridge-to-recovery strategy. Prospective registries examining interactions among cardiotoxic chemotherapy, assisted reproductive technology, preeclampsia, and PPCM outcomes are needed."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Gynecology • Heart Failure • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Hypotension • Lymphoma

Economics Of Inpatient Diuretic Therapy For Heart Failure In The United States And Implications Of Shifting To Use Of Outpatient Bumetanide Nasal Spray [Poster no. 229] (HFSA 2026) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Comparing Loop Diuretics: Furosemide Versus Bumetanide. (PubMed, Cardiol Rev) - "As they both possess side effects that can be caused by low electrolyte levels, it is important to monitor these values during administration. Furosemide possesses a lower relative dose ratio to bumetanide, allowing the dosage to be more easily titrated for individual requirements, while bumetanide has a lower risk of ototoxicity and has a higher bioavailability."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology • Hypertension • Liver Failure

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial completion date: Jul 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Nov 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Functional Reelin signaling deficits without interneuron loss are associated with neuroblast misplacement after non-convulsive status epilepticus. (PubMed, Neurobiol Dis) - "Here, we investigated early dentate gyrus alterations after pilocarpine-induced NCSE, focusing on whether neuroblast misplacement is associated with loss of Reelin-positive hilar interneurons or with functional impairment of Reelin signaling. Two-day bumetanide treatment improved selected post-NCSE alterations, including extracellular Reelin processing, RGL-neuroblast contacts, intracellular Reelin clustering and EGR1 expression in Reelin-positive interneurons, and is therefore used here as a pharmacological probe of chloride-transport-associated mechanisms rather than as definitive evidence for direct central NKCC1 inhibition or therapeutic efficacy. These findings highlight NCSE as a distinct pathological entity and suggest that chloride-transport-sensitive changes in interneuron functional state may influence Reelin signaling and neuroblast positioning after seizures."

Journal • CNS Disorders • Critical care • Epilepsy • EGR1 • GFAP

Strategies for mitigating nitrosamine contamination in pharmaceutical drug manufacturing: insights from FDA research (ACS-Fall 2026) - "The findings of this study demonstrated that incorporating antioxidants into drug formulations can effectively inhibit the formation of N-nitrosamine impurities in metformin and bumetanide formulations. This research underscores the importance of formulation design in mitigating nitrosamine risks and enhances understanding of effective approaches to ensure the safety and quality of pharmaceutical products."

Application of molecularly imprinted polymers on carbon dots for fluorescence detection of bumetanide in adulterated dietary supplements: instrumental and paper-based approaches. (PubMed, Anal Methods) - "The two-detection approach fluorescent system was successfully used for the identification of BUM in complicated dietary supplements, such as herbal teas, capsules, and sachets. The proposed instrument-based and paper-based sensing strategies provide cost-effective, end-user-friendly, and durable remedies to the regular screening and point-of-care screening of illicit adulterants in dietary supplements."

Journal

The malignant synapse: architecture, signal integration, and therapeutic vulnerabilities in glioma. (PubMed, Cell Oncol (Dordr)) - "We systematically evaluate pharmacological strategies to disconnect these malignant circuits, highlighting the repurposing of neuroactive drugs-including perampanel, gabapentin, and bumetanide-to effectively stall tumor progression. We also outline future frontiers, particularly leveraging spatial multi-omics to decode how synaptic signaling orchestrates the tumor immune microenvironment. Ultimately, dismantling the neuron-glioma axis represents a transformative frontier in conquering intractable brain cancers."

Journal • Review • Brain Cancer • Glioma • Oncology • Solid Tumor • CHRM3 • CSPG4 • NTRK2

The NKCC1 Antagonist Bumetanide, Administered After Prenatal Alcohol Exposure, Mitigates Ethanol-Induced Aberrance in Tangential Migration of GABAergic Interneurons in Mouse Medial Prefrontal Cortex. (PubMed, Alcohol Clin Exp Res (Hoboken)) - "These results indicate that blocking the NKCC1 chloride importer bumetanide can mitigate PreEE-induced interneuronopathy when administered after PreEE, implicating NKCC1 as a potential pharmacological target for post-PreEE therapeutic intervention of FASD."

Journal • Preclinical • CNS Disorders • SLC12A2

Brain Sex Steroid-Mediated Intergenerational Sex-Specific Neurocognitive Effects of Paternal Sevoflurane Exposure in Rats. (PubMed, Anesth Analg) - "These findings suggest that male-specific neurodevelopmental abnormalities following paternal preconception sevoflurane exposure arise from stress- and inflammation-programmed increases in brain-derived testosterone during the critical brain masculinization period, involving both AR and E2 signaling."

Journal • Preclinical • CNS Disorders • Developmental Disorders • Inflammation • Mood Disorders • Psychiatry • AR • ER

Bumetanide As A Candidate Therapy For Alzheimer's Disease: Insights From Retrospective Clinical Databases And Preclinical Models (AAIC 2026) - No abstract available

Preclinical • Retrospective data • Alzheimer's Disease • CNS Disorders

Pharmacological NKCC1 inhibition prevents intergenerational microbiome and neurobehavioral abnormalities following maternal preconception TBI (CINP 2026) - "Maternal preconception moderate TBI induces persistent stress and inflammatory dysregulation in dams, as well as sex-dependent gut microbiota and neurobehavioral abnormalities in offspring through both prenatal and postnatal pathways. The absence of growth deficits in foster pups and the lack of overt changes in F0F_T caregiving behavior suggest that rather than "physical" factors (e.g., nursing, licking), "social" interactions between mother and offspring, likely involving dysregulated stress and inflammatory signaling, were major contributors to postnatal maternal influences. Bumetanide prevented all abnormalities, implicating maternal stress and inflammation as key drivers of both pre- and postnatal effects and identifying NKCC1 as a potential therapeutic target.Funding: NIH (R01HD107722, R56HD102898 to A.E.M.; IHAF to Z.A.K."

CNS Disorders • Inflammation • Vascular Neurology • RBL2

When the TSH Rises: Hypothyroidism as a Clue to Inadequate Diuretic Response (ENDO 2026) - "She was initially treated with bumetanide, followed by a trial of torsemide, and subsequently transitioned to a combination of oral furosemide and metolazone due to persistent volume overload and inadequate diuretic response...Given her reported medication adherence, her profound hypothyroidism was attributed to impaired gastrointestinal absorption of levothyroxine in the setting of significant fluid overload and gut edema. This case highlights that persistent hypothyroidism in patients with decompensated heart failure may serve as an indirect marker of long-standing, refractory volume overload. TSH evaluation could potentially be a useful adjunct in assessing the duration and severity of diuretic resistance, particularly when compliance with thyroid replacement therapy is not in question."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Endocrine Disorders • Gout • Heart Failure • Hypotension • Inflammatory Arthritis • Nephrology • Renal Disease

BUFF: Bumetanide vs. Furosemide in Cirrhosis (clinicaltrials.gov) - P3 | N=500 | Recruiting | Sponsor: Stacy Johnson | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Immunology

Dim light at night induces cardiac injury in zebrafish embryos via disrupted chloride homeostasis. (PubMed, iScience) - "Genetic knockdown of zclca1 recapitulated core dLAN pathologies, while pharmacological intervention with the chloride-modulating diuretic bumetanide reversed cardiac dysfunction in both species. These findings identify a conserved "dLAN-CLCA-chloride-cardiac injury" axis, wherein light pollution disrupts chloride homeostasis to drive cardiac pathology, suggesting that chloride modulation may represent a potential therapeutic strategy for mitigating light pollution-induced cardiovascular injury."

Journal • Cardiovascular

Comparative Efficacy and Acceptability of Non-pharmacological Therapies and Novel Pharmacotherapies for Autism: A Systematic Review and Network Meta-Analysis. (PubMed, Child Psychiatry Hum Dev) - "The cannabinoids group has a lower acceptance rate than most of the other groups. Exercise, acupuncture, non-invasive brain stimulation, and bumetanide can improve the core symptoms of autism and can be used as an alternative or adjunct to autism treatment, but more clinical trials are still needed to support this outcome."

Journal • Retrospective data • Review • Autism Spectrum Disorder • Genetic Disorders

Role of GABAA receptors and chloride transporters in autism - An explorative analysis using peripheral blood as a model. (PubMed, Mol Biol Rep) - "Overall, the findings demonstrated an association between altered peripheral GABA-related gene expression, disrupted chloride homeostasis and autism pathology for the first time in an affected Indo-Caucasoid population from West Bengal, India."

Journal • Autism Spectrum Disorder • Genetic Disorders

A Case for Intranasal Bumetanide for the Management of Heart Failure. (PubMed, ESC Heart Fail) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Diuretic inhibition of experimental myopia implicates retinal ion-driven efflux in the regulation of ocular growth. (PubMed, Front Med (Lausanne)) - "We have previously suggested that ocular volume regulation is related to the rate of Retinal Ion-Driven fluid Efflux from the vitreous to the lymphatic sinusoids of the choroid, and predict that common clinically approved diuretics (amiloride, bumetanide, and furosemide) known to act on different ion exchanger and cation-chloride symporter mechanisms in retina and RPE would show differential, sign-dependent effects on refractive compensation to optical defocusing lenses that normally induce myopia and hyperopia (long-sightedness) in chick. Thus, diuretics that alter retinal function and associated ion-driven transretinal/RPE fluid efflux from vitreous to choroid inhibit the induction of defocus-induced refractive errors. This highlights the potential of diuretic-like agents for the therapeutic management of myopia and associated myopia-induced ocular pathology."

Journal • Ophthalmology

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1 (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Yale University | Trial completion date: Nov 2026 ➔ May 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

MsDR Aim 3: Mechanisms of Diuretic Resistance in Heart Failure, Aim 3 (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Yale University | Trial completion date: Mar 2028 ➔ Mar 2029 | Trial primary completion date: Mar 2028 ➔ Mar 2029

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

MsDR 2: Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Yale University | Trial completion date: Jun 2027 ➔ Jun 2028 | Trial primary completion date: Jun 2027 ➔ Jun 2028

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • CD9 • SLC26A4